Neuroblastoma - historical

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor transclusions

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main neuroblastoma page for current regimens.

2 regimens on this page
2 variants on this page


High Risk

COG ANBL0532 Regimen A

Induction,

Chemotherapy, Cycle 1 (CPM + TOPO)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once daily on days 1 through 5
    • > 12 kg: 400 mg/m2 IV over 30 to 60 minutes once daily on days 1 through 5

21 Day Cycle

Chemotherapy, Cycle 2 (CPM + TOPO)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once daily on days 1 through 5
    • > 12 kg: 400 mg/m2 IV over 30 to 60 minutes once daily on days 1 through 5

21 Day Cycle

Supportive Therapy, Cycle 2

  • Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily on Day 6 beginning 24 hours after completion of chemotherapy and continuing until ANC > 1000/μL
  • Filgrastim (Neupogen) 10 μg/kg SubQ or IV once daily beginning once ANC > 1000/μL and continuing until PBSC harvest is complete
  • PBSC harvest on day 14

21 Day Cycle

Chemotherapy, Cycle 3 (CDDP + ETOP)

  • Cisplatin (Platinol) by the following weight-based criteria:
    • ≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 1 through 4
    • > 12 kg: 50 mg/m2 IV over 1 hour once daily on days 1 through 4
  • Etoposide (Vepesid) by the following weight-based criteria:
    • ≤ 12 kg: 6.67 mg/kg IV over 1 hour once daily on days 1 through 3
    • > 12 kg: 200 mg/m2 IV over 1 hour once daily on days 1 through 3

Chemotherapy, Cycle 4 (CPM + DOXO + VCR)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 70 mg/kg iV over 6 hours once daily on days 1 through 2
    • > 12 kg: 2100 mg/m2 IV over 6 hours once daily on days 1 through 2
  • Vincristine (Oncovin) by the following criteria:
    • < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
    • ≥ 12 months and > 12 kg: 0.097 mg/m2 or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
    • ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
  • Doxorubicin (Adriamycin) by the following weight-based criteria:
    • ≤ 12 kg: 0.83 mg/kg iV over 24 hours once daily on days 1 through 3
    • > 12 kg: 25 mg/m2 IV over 24 hours once daily on days 1 through 3

21 Day Cycle

Supportive Therapy, Cycle 4 (CPM + DOXO + VCR)

21 Day Cycle

Chemotherapy, Cycle 5 (CDDP + ETOP)

  • Cisplatin (Platinol) by the following weight-based criteria:
    • ≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 1 through 4
    • > 12 kg: 50 mg/m2 IV over 1 hour once daily on days 1 through 4
  • Etoposide (Vepesid) by the following weight-based criteria:
    • ≤ 12 kg: 6.67 mg/kg IV over 1 hour once daily on days 1 through 3
    • > 12 kg: 200 mg/m2 IV over 1 hour once daily on days 1 through 3

21 Day Cycle

Chemotherapy, Cycle 6 (CPM + DOXO + VCR)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 70 mg/kg iV over 6 hours once daily on days 1 through 2
    • > 12 kg: 2100 mg/m2 IV over 6 hours once daily on days 1 through 2
  • Vincristine (Oncovin) by the following criteria:
    • < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
    • ≥ 12 months and > 12 kg: 0.097 mg/m2 or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
    • ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
  • Doxorubicin (Adriamycin) by the following weight-based criteria:
    • ≤ 12 kg: 0.83 mg/kg iV over 24 hours once daily on days 1 through 3
    • > 12 kg: 25 mg/m2 IV over 24 hours once daily on days 1 through 3

21 Day Cycle

Supportive Therapy, Cycle 6 (CPM + DOXO + VCR)

21 Day Cycle

Consolidation,

Chemotherapy, High Dose with PBSC Support

  • Thiotepa (Thioplex) by the following weight-based criteria:
    • ≤ 12 kg: 10 mg/kg IV over 2 hours once daily on days -7, -6, -5
    • > 12 kg: 300 mg//m2 IV over 2 hours once daily on days -7, -6, -5
  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 50mg/kg IV over 1 hour once daily on days -5, -4, -3, -2
    • > 12 kg: 1500 mg/m2 IV over 1 hour once daily on days -5, -4, -3, -2
  • PBSC on day 0

Supportive therapy,

  • Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily starting on day 0 and continuing until post-nadir ANC > 2000/μL for 3 consecutive days

50 Day Cycle

Maintenance, 6 Cycles

Chemotherapy,

  • Isotretinoin (Accutane) by the following weight-based criteria:
    • ≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice daily on days 1 through 14
    • > 12 kg: 160 mg/m2 (Round dose to nearest 10 mg) PO twice daily on days 1 through 14

28 Day Cycle

References

  1. COG ANBL0532:Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul;48(7):947-52. link to original article link to PMC article PubMed